Teva Pharmaceutical Industries
Open
$35.27
Prev. Close
$35.27
High
$35.33
Low
$35.07
Market Snapshot
$40.59B
28.8
-1.45
$16.54B
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Teva Pharmaceutical Industries reported increased Q1 2026 earnings, driven by strong UZEDY sales and a $700 million acquisition of Emalex, enhancing future growth potential.
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. The firm operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.
Recently from Cashu
Teva Launches Home Ground Schizophrenia Community for Patient and Caregiver Support
